Anti-influenza medications such as matrix protein 2 (M2) ion channel blockers (Takeda et al., 2002) and neuraminidase (NA) inhibitors (Alymova et al., 2005) have been approved globally, while an RNA polymerase inhibitor (Hayden and Shindo, 2019), an antivirus medication, has been approved regionally (Zhang et al., 2019). This evidence concerns the gene XK and influenza.